Thrivent Financial for Lutherans Sells 12,680 Shares of Illumina, Inc. (NASDAQ:ILMN)

Thrivent Financial for Lutherans decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 20.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,069 shares of the life sciences company's stock after selling 12,680 shares during the quarter. Thrivent Financial for Lutherans' holdings in Illumina were worth $6,647,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Bleakley Financial Group LLC acquired a new stake in Illumina in the fourth quarter worth $751,000. Zacks Investment Management acquired a new stake in shares of Illumina in the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp grew its stake in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after buying an additional 22,718 shares during the period. Strategic Financial Concepts LLC bought a new stake in Illumina in the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP raised its stake in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock worth $1,001,000 after buying an additional 6,263 shares during the period. Institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on ILMN. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research note on Friday, February 28th. Royal Bank of Canada decreased their price target on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research note on Wednesday, March 12th. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Finally, Barclays restated an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $140.90.

Remove Ads

Illumina Price Performance

Shares of Illumina stock traded down $0.55 on Thursday, reaching $82.28. The stock had a trading volume of 1,812,730 shares, compared to its average volume of 2,106,132. The business's 50 day moving average is $105.03 and its two-hundred day moving average is $127.40. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market cap of $13.03 billion, a P/E ratio of -10.71, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.